Business / Finance

RSS

Targeted Medical Pharma launches new division to manufacture and distribution dietary supplements

Targeted Medical Pharma, Inc., a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced the launch of a new division that will specialize in the manufacturing and distribution of a proprietary line of dietary supplements.

30 Aug 2013

Revenue of China Nepstar Chain Drugstore for second quarter of 2013 increased by 3.4%

China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or the "Company"), the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the second quarter ended June 30, 2013.

29 Aug 2013

Teva Declines Right To License Rexahn Cancer Drug

...

28 Aug 2013

Endo Eyes Generics Growth With $225M Boca Pharmacal Acquisition

...

28 Aug 2013

University Of Virginia Gets $14.4M Grant To Fight Hypertrophic Cardiomyopathy

...

28 Aug 2013

Haplogen, Cemm Offer Huge Collection Of Mutant Cell Lines

...

27 Aug 2013

Sangamo BioSciences signs definitive agreement to buy Ceregene

Sangamo BioSciences, Inc. announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus gene therapies.

26 Aug 2013

INTEGRA Biosciences enters into UK market with local sales team

INTEGRA Biosciences has announced, as of August 1st 2013, a direct sales / support team in the UK to further improve support of its local customer base.

From INTEGRA Biosciences 23 Aug 2013

Mentors International, Co-Diagnostics HBDC to lower real-time PCR test prices in developing world

Mentors International and Co-Diagnostics HBDC signed an agreement to lower real-time PCR test prices in the developing world, starting with tuberculosis. Under the agreement, Co-Diagnostics HBDC will provide low-cost testing reagents and Mentors International will leverage its international connections to set up low-cost testing facilities.

23 Aug 2013

Shire extends existing partnership with Santaris Pharma in rare genetic disease space

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that its long term partner, Shire has extended the existing partnership in the rare genetic disease space.

23 Aug 2013

Board of Directors approve interim report for second quarter 2013

DiaGenic: The interim report for the second quarter 2013 was approved by the Board of Directors on 22 August 2013. Please find the interim report and presentation attached.

23 Aug 2013

Macrogenics Received $10M Milestone From Servier

...

22 Aug 2013

NIH Grants $5.2M To Vanderbilt Colon Cancer Investigator

...

22 Aug 2013

Takeda Launches New Subsidiary In Peru

...

22 Aug 2013

Thermo Acquisition Gets Thumbs Up From Life Tech Stockholders

...

22 Aug 2013

Psychogenics Picks Up Alzheimer’s Animal Model From USF

PsychoGenics obtained an exclusive license from the University of South Florida to its APP/PS1 double transgenic mice, which co-express the M146L presenilin 1 (PS1) mutation and the double mutations at K670N/M671L (Swedish mutation) in the amyloid precursor protein (APP).

22 Aug 2013

Caris Life Sciences to facilitate patient access to tumour profiling service in Middle East and Africa

Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of personalized medicine in oncology, has signed a distribution agreement with IPS Genomix to facilitate patient access to its tumour profiling service, Molecular Intelligence, in select Middle Eastern and African markets.

22 Aug 2013

MicuRx Pharmaceuticals raises $25 million in Series B financing

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures.

22 Aug 2013

Tel-Aviv Stock Exchange approves new listing of OPKO's common stock

OPKO Health, Inc. (NYSE: OPK), a multi-national biopharmaceutical and diagnostics company, today announced that the Tel-Aviv Stock Exchange ("TASE") has approved the new listing of OPKO's common stock on the TASE beginning on August 21, 2013, under the ticker symbol OPK. OPKO's common stock will thereafter be listed on both the NYSE in the United States and the TASE in Israel.

19 Aug 2013

Evogene announces financial results for second quarter and half year 2013

Evogene Ltd., a leader in plant genomics underlying crop productivity for the food, feed and biofuel industries, today announced its financial results for the second quarter and half year ended June 30, 2013.

19 Aug 2013